Abstract 1157P
Background
Recent studies indicate an association between immunosuppressive medication for immune-related adverse events (irAEs) and impaired survival. Whether this is related to corticosteroids or second-line immunosuppressants (IS) is unknown. We assessed the association of immunosuppressive regimens with survival in patients with melanoma.
Methods
Patients with advanced melanoma who received IS for irAEs induced by first-line anti-PD-1+/-anti-CTLA-4 were included from 11 Dutch and Belgian hospitals. Associations of cumulative and peak doses of corticosteroids and use of second-line IS with progression free survival (PFS) from start of IS and overall survival (OS) since immune checkpoint inhibitor (ICI) initiation were assessed using multivariable Cox regression. Analyses were adjusted for sex, age, stage, performance status, LDH, ICI type and irAE type.
Results
Among 382 patients with irAEs, 255 had IPI+NIVO-induced irAEs and 127 had anti-PD-1-monotherapy-induced irAEs. 268 patients received only corticosteroids; 113 patients additionally received second-line IS. High peak corticosteroid dose was associated with worse PFS (HR 1.47 95%CI 1.00-2.16) and OS (HR 2.17 95%CI 1.49-3.16). Cumulative corticosteroid dose was not associated with PFS or OS (Table). Use of second-line IS was associated with worse PFS (HR 1.57 95%CI 1.04-2.38); for OS, this was the case when correction for cumulative corticosteroid dose (HR 1.57 95%CI 1.06-2.33), but not when correcting for peak corticosteroid dose (HR 1.25 95%CI 0.84-1.85). Subgroup analyses will be presented. Table: 1157P
Association of immunosuppressive irAE management with survival
PFS HR (95%CI) since immunosuppression | OS HR (95%CI) since ICI | |
Univariable | ||
Steroid peak dose (per 100mg) | 1.90 (1.39-2.61) | 1.89 (1.39-2.57) |
Steroid cumulative dose (per 1000mg) | 1.06 (1.00-1.12) | 0.95 (0.90-1.01) |
2nd-line IS | 1.83 (1.32-2.52) | 1.43 (1.04-1.97) |
Multivariable including steroid peak dose and 2nd-line IS | ||
Steroid peak dose (per 100mg) | 1.47 (1.00-2.16) | 2.17 (1.49-3.16) |
2nd-line IS | 1.57 (1.04-2.38) | 1.25 (0.84-1.85) |
Multivariable including steroid cumulative dose and 2nd-line IS | ||
Steroid cumulative dose (per 1000mg) | 1.01 (0.94-1.08) | 0.95 (0.89-1.02) |
2nd-line IS | 1.64 (1.09-2.47) | 1.57 (1.06-2.33) |
Conclusions
Our data suggest that use of second-line immunosuppressants and high peak corticosteroid dose are associated with impaired survival among patients requiring IS for irAEs, while there is no association between cumulative corticosteroid dose and survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Medical Center Utrecht.
Funding
Has not received any funding.
Disclosure
G.A.P. Hospers: Financial Interests, Institutional, Advisory Board: Amgen, Bristol Myers Squibb, Roche, Merck Sharp & Dohme, Pfizer, Novartis, Sanofi, Pierre Fabre; Financial Interests, Institutional, Research Funding: Bristol Myers Squibb, Seerave. M.J.B. Aarts: Financial Interests, Institutional, Advisory Board: Amgen, Bristol Myers Squibb, Novartis, Merck Sharp & Dohme, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer; Financial Interests, Institutional, Research Funding: Merck-Pfizer. J.B.A.G. Haanen: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Achilles Therapeutics, Ipsen, Merck Sharp & Dohme, Merck Serono, Pfizer, Molecular Partners, Novartis, Roche, Sanofi, Third Rock Venture, Iovance Biotherapeutics; Financial Interests, Institutional, Advisory Board, SAB member: BioNTech, Immunocore, Gadeta, Instil Bio, PokeAcel, T-Knife; Financial Interests, Personal, Advisory Board, SAB member: Neogene Therapeutics, Scenic; Financial Interests, Personal, Stocks/Shares: Neogene Therapeutics; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, BioNTech US, Merck Sharp & Dohme, Amgen, Novartis, Asher Bio; Non-Financial Interests, Member: ASCO, AACR, SITC; Other, Editorial Board ESMO Open: ESMO; Other, Editor-in-Chief IOTECH: ESMO; Other, Editorial Board: Kidney Cancer. E. Kapiteijn: Financial Interests, Institutional, Advisory Board: BMS, Novartis, Pierre Fabre, Merck, Delcath, Bayer, Lilly; Financial Interests, Institutional, Coordinating PI: BMS, Pierre Fabre, Delcath. M. Labots: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Janssen-Cilag BV. A.A.M. Van der Veldt: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Merck Sharp & Dohme, Sanofi, Pfizer, Novartis, Roche, Eisai, Merck, Pierre Fabre, Ipsen. S. Aspeslagh: Financial Interests, Institutional, Advisory Board: Merck Sharp & Dohme, Sanofi, Roche, Bristol Myers Squibb, Pfizer, Ipsen, Galapagos. K.P.M. Suijkerbuijk: Financial Interests, Institutional, Advisory Board: Novartis, BMS, AbbVie, Pierre Fabre, MSD; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Grant: Novartis, TigaTx. All other authors have declared no conflicts of interest.
Resources from the same session
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13